Stock Taper
SCREENER COMPARE ANY 2 STOCKS
SPTX
SEAPORT THERAPEUTICS, INC. COMMON STOCK
NASDAQ
$24.04
▼ DOWN 8.42% (-2.21)

KEY STATISTICS

Market Cap$1.29 B
52w High$28.38
52w Low$14.85
Dividend Yield—
Frequency—
P/E-13.51
Volume144.83K
Shares Out.53.53M

COMPANY

LEADERSHIP

Daphne Zohar
CHIEF EXECUTIVE
Daphne Zohar

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 1, 2026
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
58

PRICE TARGET

Target High$50.00
Target Low$30.00
Target Median$32.00
Target Consensus$37.33

UPCOMING EARNINGS

DateNov 2, 2026
DayMonday
Rev. Est.—
NOV
2
MON

PRICE

$24.04 ▼ DOWN 8.42% (−$2.21)
$24.00$24.75$25.50$26.259:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM24.04

About Seaport Therapeutics, Inc. Common Stock

https://www.seaporttx.com ↗

Seaport Therapeutics, founded in 2024 in Boston, develops novel neuropsychiatric medicines using its proprietary Glyph platform to improve oral bioavailability and reduce side effects for conditions like depression and anxiety.

INDUSTRY

Biotechnology

A PRODUCT SEAPORT THERAPEUTICS, INC. COMMON STOCK IS KNOWN FOR

GlyphAllo™ (SPT-300)
GlyphAllo™ (SPT-300)

GlyphAllo™ (SPT-300), Seaport Therapeutics' Phase 2b oral prodrug of allopregnanolone, leverages the proprietary Glyph™ platform to offer a potentially rapid, durable treatment for Major Depressive Disorder.

COMPETITORS

COMPETITOR
ANRO COMPARE
PRAX COMPARE
RLMD COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
20
LISTED HERE
5
RANKED BY POSITION SIZE
VTS.AX
0.00% · 426.4K
SCHA
0.01% · 67.2K
SBIO
0.66% · 66.2K
WCEO
0.53% · 2.9K
TNXT
0.06% · 393

INSTITUTIONAL OWNERSHIP

SHARES OWNED
56.90%
HOLDERS
40
TOP 12 OF 40 · RANKED BY POSITION SIZE
Arch Venture Management, LLC
6.3M sh · $136.6M
General Atlantic, L.P.
6.1M sh · $132.53M
Sofinnova Investments, Inc.
3.6M sh · $77.43M
Goldman Sachs Group Inc
2.2M sh · $47.32M
Trv Gp Vi, LLC
2.1M sh · $44.77M
Canada Pension Plan Investment Board
2.0M sh · $42.91M
Jpmorgan Chase & Co
1.8M sh · $40.89M
Foresite Capital Management Vi LLC
1.8M sh · $38.65M
Price T Rowe Associates Inc /Md/
1.3M sh · $28.42M
Fmr LLC
1.2M sh · $25.74M
Bellevue Group AG
1.1M sh · $23.89M
Siren, L.L.C.
1.1M sh · $23.79M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
10 PERCENT OWNER
PureTech Health plc
Sale · 3.0M shares
2026-05-04
★
10 PERCENT OWNER
PureTech Health plc
Sale · 40.0M shares
2026-05-04
★
10 PERCENT OWNER
PureTech Health plc
Purchase · 2.7M shares
2026-05-04
★
10 PERCENT OWNER
PureTech Health plc
Purchase · 965.3K shares
2026-05-04

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY